WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system (CNS). The data were presented at the New Directions in ...

MARLBOROUGH, Mass. and EDINBURGH, United Kingdom, June 20, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced significant enhancements to its SmartWall Service Portal, introducing game-changing features such as all-new executive reports and tenant prospecting.Ideal for providers seeking to differentiate their services and turn service availability into a revenue opportunity, these new features empower provi ...

- FDA lifts PTC518 partial clinical hold based on PIVOT-HD data -- Conference call and webcast to be held June 20th at 8:00 am EDT - WARREN, N.J., June 20, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington's disease (HD) patients. At Month 12, PTC518 treatment resulted in dose-dependent lowering of mutant huntingtin (mHTT) protein in the blood and cerebrospinal fluid (CSF) in the interim cohort of patients. In addi ...

MARLBOROUGH, Mass., June 13, 2024 /PRNewswire/ -- Today, Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, announced the renewal and expansion of their agreement with A2 Hosting. A2 Hosting, a leading provider of high-performance hosting solutions, has entered into multiyear agreement, underlining their commitment to providing robust DDoS protection as a service (DDPaaS) to their customers using Corero's advanced technology. A2 Hosting has be ...

MARLBOROUGH, Mass., June 12, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, is pleased to announce that it has won ChannelVision's 2024 Visionary Spotlight Award (VSA) for Cybersecurity (Business Technology) for its market-leading Corero SmartWall ONE™ DDoS protection solution.The annual VSA competition highlights both channel and service provider innovation in communications, honoring outstanding products, services an ...

Cohen & Steers, Inc. (CNS) reported preliminary assets under management (AUM) of $80.5 billion as of May 31, 2024. This reflected growth of 4.3% from the prior month's level.The increase was mainly attributable to a market appreciation of $3.6 billion. This was partly offset by net outflows of $93 million and distributions of $150 million.Cohen & Steers recorded total institutional accounts of $32.1 billion at the end of May 2024, jumping 4.8% from the April 2024-end. Of the total institutional accounts, ad ...

NEW YORK, June 10, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $80.5 billion as of May 31, 2024, an increase of $3.3 billion from assets under management of $77.2 billion at April 30, 2024. The increase was due to market appreciation of $3.6 billion, partially offset by distributions of $150 million and net outflows of $93 million. Assets Under Management(unaudited) ($ in millions) AUM Net Market AUM By investment vehicle: 4/3 ...

koto_feja/E+ via Getty Images ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company specializing in developing treatments for central nervous system [CNS] conditions. The company has two successful FDA-approved commercial franchises, Nuplazid (pimavanserin), approved in 2016 for Parkinson’s disease psychosis, and Daybue (trofinetide), approved in March 2023 for Rett syndrome. Despite a setback with a failed clinical trial for a new indication for Nuplazid as a treatment for schizophre ...

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a br ...

NEW YORK, June 3, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that an affiliate of Cohen & Steers Capital Management, Inc. ("Cohen & Steers") and DLC Management ("DLC"), an owner and operator of open-air shopping centers in the U.S., have jointly acquired a two-property open-air shopping center complex in Fayetteville, Arkansas. The acquisition is comprised of two centers, Spring Creek Centre and Steele Crossing, and encompasses 403,000 square feet of owned retail space. The center ...